Bausch Health Companies Inc. (BHC) Stock AnalysisBHCBausch Health Companies Inc.

Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Bausch Health Companies Inc is a good buy right now due to its recent strong earnings report showing a 13% year-over-year revenue increase to $2.85 billion, which surpassed analyst expectations. Additionally, the company raised its 2026 revenue guidance to between $10.79 billion and $11.04 billion, reflecting confidence in future growth. The current price is $6.30, and the RSI is at 74.87, indicating strong momentum. The main risk is the high debt levels, with a debt-to-equity ratio of 0%, which could impact financial stability if not managed properly.